Mark Elliott Boulding, Executive VP AND CLO at PTC THERAPEUTICS, INC. (PTCT), sold 71,290 shares at $61.00 ($4.4M) on 2025-09-11, disclosed to the SEC on 2025-09-15.
Scheduled sale ($4.4M) by Executive VP AND CLO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $61.00 | 2,356 | $144K | 3.3% |
| 2 | $61.00 | 2,470 | $151K | 3.5% |
| 3 | $61.00 | 17,838 | $1.1M | 24.9% |
| 4 | $61.21 | 905 | $55K | 1.3% |
| 5 | $61.21 | 905 | $55K | 1.3% |
| 6 | $61.31 | 1,019 |
| $62K |
| 1.4% |
| 7 | $61.31 | 1,019 | $62K | 1.4% |
| 8 | $61.33 | 22,117 | $1.4M | 31.1% |
| 9 | $61.33 | 22,117 | $1.4M | 31.1% |
| 10 | $62.09 | 544 | $34K | 0.8% |
| Total | $61.23 avg | 71,290 | $4.4M | 100% |
| Filing → |
| PTCT | SELL | 2026-08-19 | $204K | — | Filing → |
| PTCT | SELL | 2026-07-08 | $432K | — | Filing → |
| PTCT | SELL | 2026-06-22 | $823K | — | Filing → |